title: Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review.
abstract: BACKGROUND
  Despite the burden of schizophrenia and bipolar disorder in the Chinese population, country-specific data to guide practitioners regarding antipsychotic therapy are lacking. The primary aim of this systematic review was to examine evidence of the efficacy, effectiveness, and safety of olanzapine in Chinese populations.
  
  
  METHODS
  A systematic literature search was conducted using databases covering international and Chinese core journals using search terms related to schizophrenia and bipolar disorder, specified countries (People's Republic of China, Hong Kong, Taiwan), and olanzapine treatment. Following initial screening, inclusion and exclusion criteria were applied to the search results to identify relevant studies from which data were extracted.
  
  
  RESULTS
  A total of 489 publications were retrieved and 61 studies were identified for inclusion. Most studies were related to schizophrenia (n=54), with six studies related to bipolar disorder and one study related to both conditions. The quality of study methods and reporting in international journals was noticeably better than in Chinese language journals. Most studies included relatively small patient populations and were of short duration. The efficacy of olanzapine in Chinese populations was confirmed by multiple comparative and noncomparative studies that found statistically significant reductions in symptom measures in studies conducted for ≥6 weeks (schizophrenia) or ≥3 weeks (bipolar disorder). Findings related to effectiveness (treatment discontinuation, quality of life, and neurocognitive improvements) were generally consistent with those observed in non-Chinese populations. No new safety signals specific for Chinese populations were raised for olanzapine.
  
  
  CONCLUSIONS
  Chinese and non-Chinese populations with schizophrenia or bipolar disorder treated with olanzapine display broadly similar responses. Differences between these populations, especially in relation to the relative efficacy of olanzapine versus other antipsychotics, may warrant further investigation via studies incorporating both populations. Use of local data to provide evidence for practice guidelines should be encouraged, and may promote ongoing improvements in the quality of research and study reporting.
authors.affiliation: Lilly Suzhou Pharmaceutical Co, Ltd, Shanghai Branch, Shanghai, People's Republic of China.
authors.forename: Hai Bo Haber
authors.initials: HB
authors.lastname: Xue
authors.affiliation: Lilly Suzhou Pharmaceutical Co, Ltd, Shanghai Branch, Shanghai, People's Republic of China.
authors.forename: Li
authors.initials: L
authors.lastname: Liu
authors.affiliation: China Pharmaceutical University, Nanjing, People's Republic of China.
authors.forename: Hena
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Eli Lilly Australia Pty Ltd, West Ryde, Australia.
authors.forename: William
authors.initials: W
authors.lastname: Montgomery
authors.affiliation: Eli Lilly & Co, Budapest, Hungary.
authors.forename: Tamás
authors.initials: T
authors.lastname: Treuer
keywords: Chinese; bipolar disorder; olanzapine; outcomes; schizophrenia